Oncology · Pancreatic CancerTrial Updateclinicalmid-term

Surufatinib Combination Trial for High-Risk Pancreatic Cancer Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 12:30:30 AM

Assessment confidence: 64% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the surufatinib combination trial represents a significant development in the treatment landscape for high-risk pancreatic cancer. As outcomes from this trial could influence treatment paradigms, pharma strategy teams must stay informed to adapt their portfolios accordingly. Regulatory context from MHRA (MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer) supports the near-term read. Assessment grounded in 25 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should monitor the trial's outcomes to assess potential shifts in treatment paradigms for pancreatic cancer. The strongest clinical anchor is A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer (ClinicalTrials.gov), entity match (gemcitabine). In Oncology · Pancreatic Cancer, 4 regulatory and 5 competitive items passed relevance filtering for Surufatinib.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from Merck's Sacituzumab Tirumotecan in TNBC Shows Potential in Combination with Pembrolizumab. This trial could position surufatinib as a key treatment option in the competitive landscape of pancreatic cancer therapies.

Regulatory Outlook

Regulatory risk is concentrated around MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer (MHRA). Entity match (gemcitabine); Regulatory pathway relevance (bla). Relevant agencies in corpus: MHRA, FDA. The trial's results may impact future regulatory submissions and approvals, particularly if the combination therapy demonstrates improved efficacy or safety profiles.

Key Risks

Elevated medium regulatory exposure for Surufatinib could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful trial outcomes could enhance surufatinib's market position, potentially increasing revenue and market share in the competitive pancreatic cancer therapy space.
Upside for Surufatinib may improve if A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · Triple-Negative Breast Cancer · Trial Update · This trial could position Merck favorably against competitors in the TNBC space, particularly those focused on chemotherapy alternatives.
Oncology · Prostate Cancer · Trial Update · If successful, this combination could enhance Merck's position in the prostate cancer treatment market, competing directly with existing therapies.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and overall survival data from the trial.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Entity match (gemcitabine); Regulatory pathway relevance (bla)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
ClinicalTrials.govhigh relevance
Entity match (gemcitabine)
FDA document
View source
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs.
ClinicalTrials.govhigh relevance
Entity match (surufatinib)
FDA document
View source
A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.govhigh relevance
Entity match (gemcitabine)
FDA document
View source
Mo-Rez in First- Line (1L) Maintenance Treatment of Non- Homologous Recombination Deficient Ovarian Cancer (HRd OC) [BEHOLD-Ovarian03]
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Merck's Sacituzumab Tirumotecan in TNBC Shows Potential in Combination with Pembrolizumab
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Pembrolizumab Plus Enzalutamide Trial in mCRPC Shows Promise for Overall Survival
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Advancements in Single-Cell and Spatial Transcriptomics for Pancreatic Cancer Insights
Humanexa Signalsmedium relevance
Moderate corpus alignment

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedhigh relevance
Entity match (surufatinib)
FDA document
View source
Integrative single-cell and spatial transcriptomic approaches to decipher the tumor microenvironment and therapeutic resistance in pancreatic cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Surufatinib
Gemcitabine

Commercial impact

medium

Successful trial outcomes could enhance surufatinib's market position, potentially increasing revenue and market share in the competitive pancreatic cancer therapy space.

Regulatory impact

medium

The trial's results may impact future regulatory submissions and approvals, particularly if the combination therapy demonstrates improved efficacy or safety profiles.

What to watch

Key milestones include interim results and overall survival data from the trial.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.